Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors

Y. Zheng,H. Zhong,F. Zhao,H. Zhou,C. Mao,W. Lv,M. Yuan,J. Qian,H. Jiang,Z. Wang,C. Xiao, J. Guo,T. Liu,W. Liu,Z.M. Wang,B. Li,M. Xia,N. Xu

ESMO Open（2023）

Cited 17|Views27
No score
Abstract
AK109 showed manageable safety profile and promising antitumor activity, supporting further clinical development in a large population.
More
Translated text
Key words
AK109,anti-VEGFR2 antibody,phase I study,solid tumors
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined